We value your privacy

We use necessary cookies to make this site work, and Google Analytics to measure visits (it sets cookies and is not affected by the choices below). With your consent, we also use our own analytics cookies to understand how the site is used and improve it. Privacy policy

XOOBAY 数贝环球
金盒集团
金盒集团

金盒集团

Premier Elite

5
Products
0
Followers
2013
Established

US Listing | China Securities Regulatory Commission Issues US Listing Feedback Comments to Health Tech Company Haoxi, Requiring Explanation of the Company’s Operational Compliance and Other Matters

US Listing | China Securities Regulatory Commission Issues US Listing Feedback Comments to Health Tech Company Haoxi, Requiring Explanation of the Company’s Operational Compliance and Other Matters

Golden Box Group | Listing Guidance | US Listing |IPO |SPAC |RTO | US Listing | Professional US Listing Guidance Institution | US Stock Listing |

US Listing News Today's Quick View!

On August 31, the International Department of the China Securities Regulatory Commission (CSRC) requested Haoxi Health Technology to submit supplementary materials for the filing of overseas issuance and listing, involving the company's equity structure, operational compliance, and specific details of the current issuance and listing plan. It is reported that Haoxi Health Technology intends to pursue a US IPO.

The CSRC requires Haoxi Health Technology to provide supplementary explanations on the following matters, and engage lawyers to conduct verification and issue clear legal opinions:

I. Regarding the company's equity structure, please explain:

(1) The consideration, pricing basis, and payment status of the purchase price and taxes (if any) when 6 individual shareholders including Fan Zhen transferred the equity of the domestic operating entity Beijing Haoxi to the WOFE company Haoxi Health in October 2022;

(2) The source of funds for shareholder Wu Hongli's subscription of the issuer's equity, and the status of fulfilling regulatory procedures such as foreign exchange management;

(3) The reasons and rationality for Beijing Haoxi to increase capital and introduce shareholders Wu Hongli, Zhao Tao, Sun Wenpu, and Li Han;

(4) The reasons and compliance of Beijing Haoxi's unpaid registered capital, and its impact on the company's operations and solvency.

II. Regarding operational compliance, please explain:

(1) Whether the company's business operations comply with provisions such as the "Measures for the Administration of Medical Advertisements" and the "Notice on In-depth Development of Internet Advertisement Rectification Work";

(2) The status and scale of personal information collected, used, analyzed, and stored, and whether the personal information protection and data security arrangements or measures adopted comply with national personal information protection laws and regulations;

(3) The basis for determining the rebate ratio, whether the internal governance and monitoring mechanisms related to the rebate model are sound, and whether there are any off-book rebates or other acts that violate laws and regulations such as the "Anti-Unfair Competition Law of the People's Republic of China".

III. Please supplement the specific details of the company's current issuance and listing plan in accordance with the requirements of the "Regulatory Rules Application Guidelines - Overseas Issuance and Listing No. 2: Guidelines for the Content and Format of Filing Materials", including but not limited to the number of shares issued, the estimated amount of funds raised, etc.

It is understood that Haoxi Health Technology is a company registered under the laws of the Cayman Islands on August 5, 2022. As a holding company without its own substantive business, the company mainly conducts business through its operating entity, which is Beijing Haoxi Digital Technology Co., Ltd., an online marketing solution provider located in China.

Beijing Haoxi Digital Technology Co., Ltd. was established in Beijing in 2018 and is an internet marketing service provider focusing on online performance. For many years, Haoxi has been rooted in the local online performance marketing field, serving leading customers in various industries at home and abroad, with its main business in the medical industry. With a team of over 100 professionals, Haoxi Culture helps customers accurately lock core goals, reduce risks, lower operating costs, and ensure greater profits through in-depth insights into strategy, creativity, media integration, and industry development. Haoxi Culture provides multi-channel marketing services, builds a stronger digital marketing grid for customers, and plans and executes personalized, coordinated marketing plans.

In terms of performance, in the past fiscal years 2021 and 2022, Haoxi Health Technology's revenue was 12.8475 million U.S. dollars and 16.1569 million U.S. dollars respectively, with corresponding net profit of 304,100 U.S. dollars and 244,600 U.S. dollars respectively.

Chinese concept stocks' U.S. listings rebound,the filing process for overseas issuance and listing of enterprises has accelerated, and2023yearthe U.S. stock market has risen strongly,Chinese companies' confidence in listing in the U.S. is growing. Jinhe Group's Xiaojin will share daily hot information on U.S. listings to help enterprises soar in their listing journey!

Disclaimer: Some information in this article is sourced from the internet. The content published in this article is for sharing purposes only. If there are any content or copyright issues, please contact us and we will handle it as soon as possible.

Originally published on 金盒企业管理集团